Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P160013/S019

Organ Care System (OCS) Lung System

TransMedics, Inc. · Decision date Oct 22, 2025

FDA DECISIONP160013/S019

What did the FDA decide?

FDA records P160013/S019 as a supplement to PMA P160013, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Oct 22, 2025.

FDA approval order statement

Changes in assembly inspection documentation
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Gastroenterology, Urology
Decision date
Oct 22, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P160013/S019
Regulatory pathway
PMA supplement
Product code
QBA
Decision code
OK30
Decision date
Oct 22, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Normothermic machine perfusion system for the preservation of standard criteria donor lungs prior to transplantation.

Product code
QBA
FDA device class
3

For the original device and its historical approval scope, see PMA P160013. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P160013 · Original PMA

    Organ Care System (OCS) Lung System

  2. P160013/S019 received

    Application receipt date recorded by FDA.

  3. P160013/S019 · FDA decision

    30-Day Notice

  4. P160013/S020 · Related supplement

    Organ Care System (OCS) Lung System

  5. P160013/S021 · Related supplement

    Organ Care System (OCS) Lung System

  6. P160013/S023 · Related supplement

    Organ Care System (OCS) Lung System

Timeline entries are records held by MedtechLedger for P160013. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P160013

Product / regulatory recordCompanyPathwayDecision dateSource
TransMedics, Inc.PMA approvalMar 22, 2018FDA
TransMedics, Inc.PMA supplementDec 16, 2025FDA
TransMedics, Inc.PMA supplementMay 13, 2026FDA
TransMedics, Inc.PMA supplementOct 28, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

TransMedics, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
200 Minuteman Rd., Suite 302, Andover, MA, 01810

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records